SOURCE: Generex Biotechnology

May 07, 2007 09:45 ET

Generex Biotechnology Announces Launch of Two OTC Products at Leading Healthcare Industry Event

WORCESTER, MA -- (MARKET WIRE) -- May 7, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it launched two new health-oriented products based upon its drug delivery expertise at The Home Health Care Efficient Program Planning Session held from May 6-9th at the Doral Tesoro Hotel & Golf Club in Fort Worth, Texas. The two products, BaBOOM!™ and GlucoBreak™, are available for sale immediately to leading retailers and drug stores nationwide.

BaBOOM!™ is an innovative, convenient and great-tasting instant energy spray that enhances energy levels for sports, work, study, travel and overall fatigue. Main ingredients include Glucose, Caffeine, Ginseng, Vitamin C, Vitamin B1, Vitamin B3, Vitamin B6, Vitamin B12. BaBOOM!™ is fat free, has under 5 calories per serving and comes in watermelon flavor. For more information visit

Energy products have become a $3 billion business since their introduction in the United States eight years ago, and are expected to accelerate profit growth for the beverage industry more than any other drink category in the next few years.

GlucoBreak™ is an innovative, convenient, great-tasting and fat-free glucose spray that is used as an aid for diets. GlucoBreak™ is used between meals as part of a daily diet routine, during exercise and before bedtime. For more information visit

According to Marketdata Enterprises, Inc. (, a leading market research publisher of service industry studies, the total U.S. weight-loss market generated sales of $55.4 billion in 2006 and should reach $58.7 billion this year and $68.7 billion by 2010. It is estimated that there are 72 million dieters -- about 70% of whom try to lose weight by themselves.

The focus of the EPPS Home Health Care event is the presentation and review of new products, marketing initiatives and promotional opportunities in the following categories: Diabetes, Home Diagnostics, Incontinence, Respiratory Products, Durable Medical Equipment, Mobility, Braces and Supports, Wound Care, Adult Nutrition, Compression Hosiery. For more information visit

The company's product Glucose RapidSpray™ was also launched at this conference last year and has been available in retail chains across the US and Canada since September 2006. The product is now expanding its distribution network in other markets around the world.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at or the Antigen Express website at

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • Contact:
    For more information, please contact:

    For Generex:
    Shayne Gilliatt
    800-391-6755 or 416-364-2551

    Andrew Hellman
    CEOcast, Inc.